Laser Power & Infra reports Q3 2026 IPO proceeds utilization

Laser Power & Infra Limited has submitted its Monitoring Agency Report for the quarter ended September 30, 2026. This report, issued by CRISIL Ratings, details the utilization of proceeds from the company’s Initial Public Offer (IPO). The filing confirms that IPO funds were allocated towards repayment/prepayment of certain outstanding borrowings and general corporate purposes, as per the offer document.

Laser Power & Infra Limited Files Q3 2026 IPO Proceeds Monitoring Report

Laser Power & Infra Limited has submitted its Monitoring Agency Report for the quarter ended September 30, 2026. This disclosure fulfills regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Key Findings from the Report

The report, prepared by CRISIL Ratings, details the utilization of proceeds from Laser Power & Infra Limited’s Initial Public Offer (IPO). The primary objects for which the funds were utilized during the quarter include:

  • Repayment/pre-payment of certain outstanding borrowing availed by the Company: A total of ₹4,900.00 million was originally allocated for this purpose, and the entire amount has been utilized.
  • General corporate purposes: An allocation of ₹211.46 million was designated for general corporate purposes. The amount utilized during the quarter was ₹211.46 million. The report notes that this utilization does not exceed 25% of the Gross Proceeds.

Issue Expenses

Issue expenses amounting to ₹308.54 million were also part of the allocation, with ₹267.40 million utilized during the quarter, leaving an unutilized balance of ₹41.14 million. This remaining amount is held in the Public Offer account of the company with ICICI Bank.

Overall Utilization

The total gross proceeds from the fresh issue were ₹5,420.00 million. As of the end of the quarter, the total utilized amount stood at ₹5,378.86 million, with an unutilized amount of ₹41.14 million.

Source: BSE

Previous Article

Zydus Lifesciences announces closure of USFDA inspection at UK facility